171 related articles for article (PubMed ID: 12006537)
1. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
[TBL] [Abstract][Full Text] [Related]
2. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
Langerød A; Bukholm IR; Bregård A; Lønning PE; Andersen TI; Rognum TO; Meling GI; Lothe RA; Børresen-Dale AL
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1684-8. PubMed ID: 12496062
[TBL] [Abstract][Full Text] [Related]
3. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Hu Y; McDermott MP; Ahrendt SA
Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
[TBL] [Abstract][Full Text] [Related]
4. Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract.
Furihata M; Kurabayashl A; Matsumoto M; Sonobe H; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
J Pathol; 2002 May; 197(1):82-8. PubMed ID: 12081208
[TBL] [Abstract][Full Text] [Related]
5. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
6. p53 Codon 72 polymorphism, loss of heterozygosity and high-risk human papillomavirus infection in a low-incidence German esophageal squamous cell carcinoma patient cohort.
Pantelis A; Pantelis D; Ruemmele P; Hartmann A; Hofstaedter F; Buettner R; Bootz F; Stoehr R
Oncol Rep; 2007 May; 17(5):1243-8. PubMed ID: 17390072
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
8. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
9. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis.
Buller RE; Sood A; Fullenkamp C; Sorosky J; Powills K; Anderson B
Cancer Gene Ther; 1997; 4(4):239-45. PubMed ID: 9253509
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
11. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
12. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer.
Lee JM; Shun CT; Wu MT; Chen YY; Yang SY; Hung HI; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
Mutat Res; 2006 Feb; 594(1-2):181-8. PubMed ID: 16318864
[TBL] [Abstract][Full Text] [Related]
13. p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck.
Scheckenbach K; Lieven O; Götte K; Bockmühl U; Zotz R; Bier H; Balz V
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1805-9. PubMed ID: 15533911
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.
Papadakis ED; Soulitzis N; Spandidos DA
Br J Cancer; 2002 Oct; 87(9):1013-8. PubMed ID: 12434294
[TBL] [Abstract][Full Text] [Related]
15. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer.
Rogounovitch TI; Saenko VA; Ashizawa K; Sedliarou IA; Namba H; Abrosimov AY; Lushnikov EF; Roumiantsev PO; Konova MV; Petoukhova NS; Tchebotareva IV; Ivanov VK; Chekin SY; Bogdanova TI; Tronko MD; Tsyb AF; Thomas GA; Yamashita S
Oncol Rep; 2006 Apr; 15(4):949-56. PubMed ID: 16525684
[TBL] [Abstract][Full Text] [Related]
16. p53 codon 72 polymorphism as a risk factor in the development of breast cancer.
Papadakis EN; Dokianakis DN; Spandidos DA
Mol Cell Biol Res Commun; 2000 Jun; 3(6):389-92. PubMed ID: 11032762
[TBL] [Abstract][Full Text] [Related]
17. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
18. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
19. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.
Schneider-Stock R; Boltze C; Peters B; Szibor R; Landt O; Meyer F; Roessner A
Neoplasia; 2004; 6(5):529-35. PubMed ID: 15548361
[TBL] [Abstract][Full Text] [Related]
20. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
